
IN8BIO (INAB) Stock Forecast & Price Target
IN8BIO (INAB) Analyst Ratings
Bulls say
IN8bio Inc shows a positive outlook due to the encouraging data surrounding its product candidate INB-100, which demonstrates a strong efficacy in preventing relapse in high-risk acute myeloid leukemia (AML) patients post-haploidentical stem cell transplantation. Notable metrics include a 100% overall survival rate at one year for patients treated with INB-100 compared to approximately 70% in historical studies, reflecting a significant improvement in treatment outcomes. Furthermore, the absence of treatment-related deaths and severe adverse events underscores the tolerability and safety profile of INB-100, reinforcing potential for successful clinical advancement and market acceptance.
Bears say
The analysis of IN8bio Inc reveals a downward adjustment in the 12-month price target from $8.00 to $6.00, indicating a cautious approach towards the stock's future performance. Despite the promising data from preclinical studies on the potential of INB-619, the overall market sentiment remains negative, potentially due to uncertainties surrounding the clinical progression of its product candidates. The focus on niche applications within oncology combined with potential challenges in commercialization may contribute to this unfavorable outlook.
This aggregate rating is based on analysts' research of IN8BIO and is not a guaranteed prediction by Public.com or investment advice.
IN8BIO (INAB) Analyst Forecast & Price Prediction
Start investing in IN8BIO (INAB)
Order type
Buy in
Order amount
Est. shares
0 shares